SCS-5735371-0/11/1

Novartis Pharmaceuticals Corporation — FEI 2210396

Refusal Details

Date
September 24, 2024
Country
United States
Product Category
Drugs and Biologics
Product Code
58ACY04 OMALIZUMAB
Charges
118,75